-
Innovent to develop & commercialize a novel diabetes medicine in China
biospectrumasia
August 22, 2019
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high-quality medicines, has announced that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for the development and potential co
-
Innovent and Shenogen study Tyvyt-SNG1005 combination for cancer
pharmaceutical-technology
August 07, 2019
Innovent Biologics and Shenogen Pharma Group have signed a collaboration agreement to evaluate the combination therapy of Innovent’s Tyvyt with Shenogen’s SNG1005, in patients with advanced cancer.
-
Innovent and Shenogen Announce Collaboration to Evaluate Tyvyt? (Sintilimab injection) in Combination with SNG1005 for the Treatment of Patients with Advanced Cancer
prnasia
August 06, 2019
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced the signing of a collaboration agreement with ...
-
Innovent Announces a Collaboration with Chipscreen Biosciences to Evaluate the Combination Therapy in Colorectal Cancer Patients
pharmafocusasia
February 19, 2019
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality innovative medicines for the treatment of oncology .....
-
Innovent Announces First Patient Dosed in Anti-CD47 Trial
americanpharmaceuticalreview
January 16, 2019
Innovent Biologics announced the first patient has been successfully dosed in a phase I clinical trial of anti-CD47 monoclonal antibody (IBI188) for patients with advanced malignancies....
-
Innovent buys Chinese rights to Incyte drugs for $40M upfront
fiercebiotech
December 18, 2018
Innovent Biologics has bagged the Chinese rights to three clinical-phase oncology and hematology drugs in development at Incyte.
-
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
pharmafocusasia
December 17, 2018
Innovent Biologics, Inc. and Incyte today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for .....
-
Innovent and Hutchison to test sintilimab and fruquintinib combination
pharmaceutical-technology
December 03, 2018
Innovent Biologics (Suzhou) has entered into a global collaboration agreement to evaluate the safety of its sintilimab in combination with Hutchison MediPharma’s fruquintinib .....
-
Innovent secures funding worth $150M
biospectrumasia
May 02, 2018
The proceeds will be used to speed up and expand the company's clinical programs.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
